Placebo‐Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome by Shneider, Benjamin L. et al.
1184
Hepatology CommuniCations, Vol. 2, no. 10, 2018  
Placebo-Controlled Randomized Trial of 
an Intestinal Bile Salt Transport Inhibitor 
for Pruritus in Alagille Syndrome
Benjamin L. Shneider,1 Cathie Spino,2 Binita M. Kamath,3 John C. Magee,4 Lee M. Bass,5 Kenneth D. Setchell,6  
Alexander Miethke,7 Jean P. Molleston,8 Cara L. Mack,9 Robert H. Squires,10 Karen F. Murray,11 Kathleen M. Loomes,12  
Philip Rosenthal,13 Saul J. Karpen,14 Daniel H. Leung,1 Stephen L. Guthery,15 Danny Thomas,16 Averell H. Sherker,17  
Ronald J. Sokol,18 and for the Childhood Liver Disease Research Network
Medically refractory, severe, cholestasis-induced pruritus in Alagille syndrome may be improved by surgical interruption of 
the enterohepatic circulation. This multicenter trial (NCT02057692) tested the hypothesis that the intestinal bile acid 
transport inhibitor maralixibat would similarly reduce pruritus in Alagille syndrome. Thirty-seven children with Alagille 
syndrome were randomly assigned to double-blinded administration of placebo, 70, 140, or 280 µg/kg/day of maralixibat for 
13 weeks. Pruritus was assessed by caregiver (itch-reported outcome instrument [ItchRO]) and clinician report (range, 0-4 
[severe]). Liver chemistries and serum bile acids were measured. The primary outcome was the change from baseline to week 
13 in ItchRO relative to placebo. In the a priori first analysis of the primary efficacy endpoint, the mean adjusted difference 
between participants receiving 140 or 280 µg/kg/day and placebo was –0.47 (95% confidence interval [CI], –1.14, 0.20; 
P = 0.16). Statistically significant decreases were observed with doses of 70 and 140 µg/kg/day (mean adjusted difference, 
–0.89; 95% CI, –1.70, –0.08; P = 0.032; and mean adjusted difference, –0.91; 95% CI, –1.62, –0.19; P = 0.014) but not 280 
µg/kg/day (mean adjusted difference, –0.04; 95% CI, –0.94, 0.86; P = 0.44) or all doses combined (mean adjusted difference, 
–0.61; 95% CI, –1.24, 0.20; P = 0.055). A 1-point reduction in pruritus was more common in maralixibat-treated versus 
placebo-treated participants (caregiver ItchRO, 65% versus 25%; P = 0.06; clinician score, 76% versus 25%; P = 0.01). There 
were no significant changes in liver chemistries or bile acids relative to placebo. Adverse and serious adverse events were 
similar between maralixibat and placebo. Conclusion: Although the prespecified primary analyses of ItchRO were not all 
statistically significant, the data suggest that maralixibat is safe and may reduce pruritus in Alagille syndrome. (Hepatology 
Communications 2018;2:1184-1198).
Abbreviations: AE, adverse event; ALGS, Alagille syndrome; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ASBT, apical sodium-
dependent bile acid transporter; ASBTi, ASBT inhibitor; C4, 7α-hydroxy-4-cholesten-3-one; CI, confidence interval; CSS, clinical scratch score; 
DB, direct bilirubin; DILI, drug-induced liver injury; GGT, gammaglutamyl transpeptidase; IE, ileal exclusion; IMAGO, Safety and efficacy 
study of LUM001 in the treatment of cholestatic liver disease in patients with Alagille syndrome; ItchRO, itch-reported outcome; ITT, intention-
to-treat population; LDL-C, low-density lipoprotein cholesterol; mITT, modified intention-to-treat population; NIDDK, National Institute of 
Diabetes and Digestive and Kidney Diseases; Obs, observation; PBC, primary biliary cholangitis; PEBD, partial external bile diversion; SBA, 
serum bile acid; TB, total bilirubin.
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Alagille syndrome (ALGS) is a rare autosomal dominant disorder, classically manifested by cholestatic liver disease and variable involve-
ment of the heart, eyes, face, skeleton, kidneys, and 
vasculature.(1) The liver disease of ALGS can present 
in infancy with marked cholestasis and fat malabsorp-
tion and with the subsequent development of intense 
pruritus that may be debilitating, causing cutaneous 
mutilation and disruption of sleep and school activi-
ties. In cholestatic liver disease, pruritus appears to be 
associated with elevated total serum bile acids (SBAs), 
although the specifics of the relationship are not well 
understood.
The management of pruritus in ALGS is challeng-
ing, and a variety of therapies are often used. These 
include antihistamines, rifampin, ursodeoxycholic acid, 
cholestyramine, naltrexone, and sertraline. Clinical 
experience suggests that these drugs have variable 
efficacy in reducing pruritus; however, no prospective 
clinical trial has quantified the effect of any of these 
therapies, either alone or in combination. Partial exter-
nal bile diversion (PEBD) or ileal exclusion (IE), both 
of which interrupt the enterohepatic circulation, have 
had moderate success in reducing pruritus in patients 
with ALGS; however, the procedures require surgery, 
and biliary diversion presents the long-term burden of 
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caring for a stoma.(2,3) Thus, refractory pruritus is, in 
some circumstances, an indication for liver transplan-
tation in ALGS. Hence, there is an unmet need for the 
development and testing of improved medical thera-
pies for ALGS-associated pruritus.
Maralixibat (SHP625, LUM001; Shire) is a 
potent inhibitor of the ileal bile acid transporter/api-
cal sodium-dependent bile acid transporter (ASBT) 
(SLC10A2), which was initially developed as a cho-
lesterol-lowering agent. This transporter mediates the 
uptake of conjugated bile acids across the brush border 
membrane of the ileal enterocyte from where they are 
ultimately transported to the liver in the enterohepatic 
circulation. ASBT expression is under negative feed-
back regulation by luminal bile acids; thus, in the set-
ting of cholestasis and reduced intraluminal bile acid 
concentrations, ASBT is maladaptively up-regulated.(4,5) 
Therefore, inhibiting the ileal reabsorption of bile acids 
may represent a useful strategy for reducing SBAs in 
cholestatic disease and potentially reducing pruritus.(6) 
Because PEBD and IE have been shown to reduce SBAs 
and improve pruritus and xanthomas in ALGS, pharma-
cologic blockade of intestinal re-uptake of bile acids with 
an ASBT inhibitor (ASBTi) may be a viable alternative 
to surgical intervention for pruritus in ALGS.(3,7)
We conducted a randomized, double-blind, pla-
cebo-controlled, parallel group, multicenter trial of 
maralixibat in children with ALGS and pruritus. The 
study was designed to determine the effects of gradu-
ated doses of maralixibat for 13 weeks compared with 
placebo on pruritus, SBAs, liver enzymes, and other 
biochemical markers associated with cholestatic liver 
disease. The itch-reported outcome (ItchRO) instru-
ment, a novel tool to assess pruritus, was administered 
through an electronic diary to capture twice-daily 
 pruritus scores, the primary endpoint for this study.(8)
Participants and Methods
study population
This study enrolled children aged 1 year through 
18 years who had cholestasis and pruritus caused by 
ALGS, which was diagnosed based on study criteria 
(Supporting Table S1) and confirmed by JAGGED1 
or NOTCH2 genotyping. Eligibility (i.e., presence of 
significant pruritus) was determined using twice-daily 
caregiver-based assessment of pruritus by ItchRO 
observation of child reported by parent/guardian/care-
giver (Obs).(8) ItchRO scores range from 0 to 4, with 
higher scores indicating increasing pruritus severity. 
The average daily score was derived from the highest 
score of the morning and evening observations, which 
reflects the worst pruritus of that day. Eligibility for 
this study required an average daily ItchRO(Obs) score 
of ≥2 for 2 consecutive weeks. Patients were excluded 
if they had chronic diarrhea requiring intervention, 
surgical interruption of the enterohepatic circulation, 
prior liver transplant, alanine aminotransferase (ALT) 
>15 times the upper limit of normal or decompensated 
cirrhosis (full inclusion and exclusion criteria are listed 
in Supporting Table S2).
Written informed consent was obtained from care-
givers, and assent was obtained when appropriate 
from the child according to local institutional review 
board rules. This study was approved by local institu-
tional review boards, complied with the Declaration of 
Helsinki and Good Clinical Practice Guidelines, and 
was registered at ClinicalTrials.gov (NCT02057692). 
The study was developed with and conducted in col-
laboration with Lumena Pharmaceuticals, now part 
of the Shire Group of Companies, in the context of 
a Cooperative Research and Development Agreement 
with the National Institute of Diabetes and Digestive 
and Kidney Diseases (NIDDK). Lumena/Shire was 
not involved in the data analysis or the reporting and 
interpretation of the results, which were independently 
performed by the NIDDK-funded Childhood 
Liver Disease Research Network. As set out by the 
Cooperative Research and Development Agreement, 
Lumena/Shire was permitted to read and comment on 
the manuscript prior to submission.
study design
This was a double-blind, randomized, placebo- 
controlled phase 2b trial conducted at 12 NIDDK-
funded Childhood Liver Disease Research Network 
sites (listed in Supporting Table S3). Originally, partic-
ipants were randomized to one of three treatment arms 
in a 2:1 randomization ratio between maralixibat and 
placebo (n = 8 each in placebo, 70 µg/kg/day, or 140 
µg/kg/day), with the primary comparison between the 
pooled maralixibat groups and placebo. Approximately 
1 year after the start of the study (after 9 participants 
had begun investigational drug administration), an 
additional higher dose arm (280 µg/kg/day, n = 8) was 
added to the study based on preliminary results from 
a similar but smaller study conducted in the United 
Kingdom (Safety and efficacy study of LUM001 in the 
treatment of cholestatic liver disease in patients with 
Alagille syndrome [IMAGO]; design and preliminary 
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results reported [NCT01903460]). To maintain the 
original design features of a 2:1 randomization ratio 
between placebo and active drug, 4 additional par-
ticipants were randomized to placebo (n = 12 total), 
and the primary comparison became the pooled two 
highest tolerated active doses versus placebo. A dose 
was considered “not tolerated” if >50% of participants 
in that dose cohort did not tolerate the treatment, as 
evidenced by dose reduction, suspension, or discon-
tinuation due to gastrointestinal tolerability related to 
maralixibat.
Randomization was performed by the central phar-
macy using schedules (original and amended) that were 
prepared by a clinical research organization. Permuted 
blocks of size 3 and size 9 were used for the original 
design and the amended study, respectively. The care-
givers, participants, investigators, and the sponsor were 
unaware of treatment assignment until the last partic-
ipants completed week 13, at which time the database 
was locked and the blind broken.
The study drug was administered once daily in the 
morning at least 30 minutes prior to breakfast. Dosing 
was escalated over 5 weeks to enhance tolerability of 
the study drug (Fig. 1). The final dose of the study drug 
was then maintained for 8 weeks. Study visits occurred 
at weeks 0, 2, 4, 8, and 13 and phone interviews at 
weeks 1, 3, and 6. Changes in the use of antipruritic 
medications during the study were not permitted.
The primary endpoint was the change in pruritus 
as measured by the ItchRO(Obs). The average daily 
ItchRO(Obs) score for 7 days pretreatment was com-
pared with the last 7 days of treatment (i.e., change from 
baseline to week 13 or end of treatment for those who 
discontinued early [designated week 13]). Secondary 
endpoints included changes from baseline to week 13 
for SBAs, ALT, aspartate aminotransferase, alkaline 
phosphatase (ALP), gammaglutamyl transpeptidase 
(GGT), total bilirubin (TB), and direct bilirubin (DB).
Other efficacy endpoints included changes 
from baseline over time (weeks 2, 4, 8, and 13) for 
ItchRO(Obs), SBAs, ALT, ALP, GGT, TB, DB, total 
cholesterol, low-density lipoprotein cholesterol (LDL-
C), and 7α-hydroxy-4-cholesten-3-one (C4; surro-
gate marker of bile acid biosynthesis). Changes from 
baseline in the clinical scratch score (CSS; Supporting 
Table S4), which has been used in pediatric studies(9) 
and is based on a scale developed by Whitington,(7) 
were examined. Changes from baseline for ItchRO 
completed by participants if ≥9 years old or by caregiv-
ers with input from participants 5-8 years old as well 
as xanthoma severity (Supporting Table S5) were also 
assessed.(2) SBAs were quantified by stable-isotope dilu-
tion analysis using liquid chromatography-electrospray 
ionization-mass spectrometry (Division of Pathology 
and Laboratory Medicine, Cincinnati Children’s 
Hospital Medical Center, Cincinnati, OH).(10)
Fig. 1. Study schema.
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Adverse events (AEs), serious AEs, treatment dis-
continuations due to AEs, and AEs of special interest 
(e.g., gastrointestinal symptoms, liver injury, fat-soluble 
vitamin level abnormalities, and growth retardation) 




The planned sample size of 36 evaluable subjects 
with ALGS was based on practical considerations 
rather than a desired power for a prespecified differ-
ence. With the proposed sample of 28 subjects for the 
primary efficacy analyses (16 maralixibat from the two 
highest tolerated doses and 12 placebo), there would 
be 80% power to detect an effect size of ≥1.12, using a 
two-sided type I error of 5% and a two-sample t test. 
Analyses were not adjusted for multiple comparisons, 
and nominal P values are reported.
analytic methods
Efficacy analyses were performed using the modi-
fied intention-to-treat population (mITT), defined as 
all participants randomized, receiving at least one dose 
of study drug, and having at least one postbaseline effi-
cacy assessment. Participants were analyzed by assigned 
treatment. Sensitivity analyses were performed using 
the per protocol population, defined as the mITT pop-
ulation that did not have a major protocol violation and 
the pure ITT population (all randomized and dosed 
participants) if it differed from the mITT (which it 
did not). For participants who prematurely discontin-
ued from the study, a last observation carried forward 
approach, which only used values within 7 days of the 
last dose of study drug, was used to impute missing 
efficacy values. Safety, subject disposition, and baseline 
characteristics were analyzed using the safety pop-
ulation, defined as all randomized participants who 
received at least one dose of study drug. Participants 
were analyzed by treatment received. Statistical signifi-
cance was defined as P < 0.05; no adjustments for mul-
tiplicity were applied in this phase 2b study.
For efficacy analyses, the first statistical test per-
formed for each primary and secondary outcome 
measure was the comparison between the two high-
est tolerated active-dose groups combined (designated 
hereafter as maralixibat*) and placebo. In addition, all 
active doses combined (designated as maralixibata) 
as well as each individual dose were compared with 
placebo.
Treatment comparisons of the primary endpoint 
and of secondary and exploratory efficacy endpoints 
that were continuous were made using an analysis of 
covariance model with treatment and baseline mea-
sures as covariates. Estimates of least squares mean 
changes and associated SEMs and 95% confidence 
intervals (CIs) were reported. Active treatment groups 
(combined and individual) were tested against the pla-
cebo group, with adjusted mean treatment difference, 
SEM, 95% CI, and pairwise P value reported. In addi-
tion, changes from baseline to each visit were summa-
rized and tested. Analyses of discrete outcomes were 
analyzed using the Fisher’s exact test or the Cochran-
Mantel-Haenszel test.
Exploratory responder analyses were defined a priori 
for ItchRO(Obs) (responder if change from baseline 
to week 13 was ≤–1 or ≤–2), CSS (responder if change 
from baseline to week 13 was ≤–1), and clinician xan-
thoma scale (responder if change from baseline to week 
13 was ≤–1) and analyzed using the Fisher’s exact test.
Results
partiCipant CHaraCteristiCs
Fifty-three participants were enrolled and assessed 
for eligibility. Of these, 37 were randomized to the 
investigational drug between November 24, 2014, and 
November 16, 2016 (Fig. 2). Fifteen participants failed 
the screening ItchRO(Obs) criteria and therefore were 
ineligible. Twenty-five participants received maralixibat 
(8-70 µg/kg/day, 11-140 µg/kg/day, 6-280 µg/kg/day) 
and 12 received placebo. All but 2 participants com-
pleted the 13-week treatment period; 1 participant on 
placebo was lost to follow-up on day 28 and 1 partici-
pant who was randomized to 70 µg/kg/day withdrew 
on day 1 with a rash and elevated liver biochemistries 
after receiving one dose (14 µg/kg). The mean age of 
participants was 6.8 years, and the majority (65%) were 
between 2 and 8 years old. All had a history of antipru-
ritic medication use, prescribed as per clinical practice 
prior to enrollment (antihistamines, 73%; ursodeoxy-
cholic acid, 84%; rifampin, 68%). Laboratory parame-
ters were characteristic of individuals with cholestasis 
and ALGS (mean SBAs, 216.3 µM; ALT, 158.7 IU/L; 
GGT, 494.9 IU/L; TB, 5.3 mg/dL; total cholesterol, 
405.7 mg/dL). Baseline characteristics were similar 
among the four groups (Supporting Table S6).
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eFFiCaCy
In this phase 2b study, maralixibat*, maralixibata, 
and each individual dose of maralixibat were compared 
relative to placebo for the primary efficacy endpoint of 
change in pruritus, as measured by ItchRO(Obs) from 
baseline to week 13 (Table 1). In the first analysis of 
the primary efficacy endpoint, the mean adjusted dif-
ference between maralixibat* and placebo was –0.47 
(95% CI, –1.14, 0.20; P = 0.16). Relative to placebo, 
significant decreases were observed with the individual 
doses of 70 and 140 µg/kg/day (mean adjusted differ-
ence, –0.89; P = 0.032; and mean adjusted difference, 
–0.91; P = 0.014, respectively). No change was observed 
in the group receiving 280 µg/kg/day (mean adjusted 
difference, –0.04; P = 0.44). The change in maralixi-
bata relative to placebo was not statistically significant 
(mean adjusted difference, 0.61; P = 0.055).
Compared with baseline, the placebo group had 
a significant decrease in ItchRO(Obs) at week 13 
(mean adjusted difference, –0.58; P = 0.024). Individual 
Fig. 2. Consolidated standards of reporting trials diagram.
taBle 1. analysis oF primary endpoint: CHange From Baseline to WeeK 13 in itCHro(oBs)
Change From Baseline Treatment Compared to Placebo








(SEM) 95% CI P value
Difference in 
LS Means 
(SEM) 95% CI P value
ItchRO(Obs) average daily score
 70 μg/kg/day 8 3.2 (0.23) –1.5 (0.30) (–2.1, –0.9) <.001 –0.89 (0.40) (–1.70, –0.08) 0.032
 140 μg/kg/day 11 2.7 (0.16) –1.5 (0.26) (–2.0, –1.0) <.001 –0.91 (0.35) (–1.62, –0.19) 0.014
 280 μg/kg/day 6 3.3 (0.24) –0.6 (0.36) (–1.3, 0.1) 0.093 –0.04 (0.44) (–0.94, 0.86) 0.930
 Maralixibat* 17 2.9 (0.15) –1.1 (0.21) (–1.5, –0.6) <.001 –0.47 (0.33) (–1.14, 0.20) 0.159
 Maralixibata 25 3.0 (0.13) –1.2 (0.18) (–1.6, –0.8) <.001 –0.61 (0.31) (–1.24, 0.01) 0.055
 Placebo 12 2.8 (0.15) –0.6 (0.25) (–1.1, –0.1) 0.024
Note: Abbreviation: LS, least squares.
sHneider et al. Hepatology CommuniCations, october 2018
1190
responses over time to maralixibat or placebo are illus-
trated in Fig. 3. The mean reduction from baseline in 
ItchRO(Obs) was similar among groups in the first 2-4 
weeks of the study during dose escalation as all partici-
pants received the same doses of study drug. There was 
accentuation of the response after 4 weeks in the groups 
receiving 70 and 140 µg/kg/day when participants were 
receiving their maximal dose of maralixibat (Fig. 4).
Changes from baseline to week 13 in SBAs and liver 
biochemistries were assessed as secondary endpoints 
(Table 2; Supporting Table S7). Individual responses 
over time for SBAs and C4 are shown in Supporting 
Fig. S1. TB and DB tended to decrease in participants 
receiving maralixibat, with significant decreases from 
baseline to week 13 observed for maralixibat* and 
maralixibata (Table 2; Supporting Table S7); however, 
when these changes were compared with the placebo 
group, which showed no statistically significant change 
in TB or DB, the changes in the maralixbat* and mara-
lixibata groups were no longer statistically significant. 
For ALT, there were statistically insignificant increases 
during maralixibat treatment (Table 2). Pooled data 
over time for TB and ALT for maralixibat-treated and 
placebo-treated participants are presented in Fig. 5. 
No changes in GGT, ALP, or total cholesterol were 
observed (Supporting Table S7). Individual responses 
over time for TB and ALT are shown in Supporting 
Fig. S1. LDL-C but not total cholesterol was signifi-
cantly reduced relative to placebo with maralixibat* 
treatment (Supporting Table S7). SBAs were variable 
Fig. 3. Spaghetti plots of changes in ItchRO(Obs) over time. Each line represents an individual participant. The participants are 
grouped by the target dose of the study drug.
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and were not significantly reduced during maralixibat 
treatment (Table 2; Fig. 5). C4 tended to increase with 
therapy, although the changes were not significant and 
the levels were highly variable (Table 2; Fig. 5). One 
participant receiving 70 µg/kg/day of maralixibat had 
extraordinarily high baseline SBAs (1,014 µmol/L) and 
C4 (161.9 ng/mL). Pooled data for those participants 
receiving maralixibat revealed a reduction in SBAs in 
the first 4 weeks of the study, with a potentially com-
pensatory increase in C4 by week 8 (Fig. 5).
Additional responder analyses were conducted to 
further assess the impact of maralixibat on pruritus. 
Only 5 participants (4 on maralixibat and 1 on placebo) 
had a decrease of at least 2 units in ItchRO(Obs), and 
none of the maralixibat groups yielded a significant 
difference relative to placebo (Supporting Table S8). 
With a less stringent threshold of –1, overall response 
rates were higher and significantly greater in maralixi-
bata (68% versus 25%, P = 0.03; Supporting Table S8). 
ItchRO completed by participants if ≥9 years old or 
by caregivers with input from participants 5-8 years 
old could only be assessed in 23 of the study partici-
pants (Supporting Table S9). The improvement in the 
placebo group was nearly the same as maralixibat* and 
maralixibata (mean adjusted difference, –1.189; SEM, 
0.3734; P = 0.843; and mean adjusted difference, –1.281; 
SEM, 0.2831; P = 0.685, respectively). Maralixibat 
had a significant impact on changes from baseline 
to week 13 in CSS. Improvement was significantly 
greater in maraxibat*, maralixibata, 140, and 280 µg 
groups relative to placebo (Supporting Table S10). 
Using a predefined responder analysis at a cutoff of ≤–1 
and a post-hoc cutoff of ≤–3, significant changes from 
baseline to week 13 were observed for maralixibat* ver-
sus placebo (76% versus 25%, P = 0.01; and 35% ver-
sus 0%, P = 0.028, respectively; Supporting Table S10). 
Individual changes over time for CSS are shown in 
Fig. 6. Changes in xanthomas with maralixibat* treat-
ment were not significant (31% versus 9%, P = 0.350; 
Supporting Table S11).
Fig. 4. Pooled analysis of change from baseline of ItchRO(Obs). Mean change from baseline in ItchRO(Obs) was pooled among 
participants receiving the same dose of maralixibat. Dashed lines represent the transition of some participants to a new dose of 
maralixibat.
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saFety
No deaths occurred during the study. One serious AE 
of vomiting occurred that led to hospitalization in a par-
ticipant receiving 70 µg/kg/day of maralixibat; this was 
not felt to be related to the study drug. Maralixibat was 
stopped in the first week of the study for 1 participant 
who developed a rash and elevated ALT; the investigator 
considered this unlikely to be related to the study drug. 
Treatment-emergent AEs were common and compa-
rable in participants receiving maralixibat and placebo 
(Supporting Table S12). Given the proposed mechanism 
of action of maralixibat, gastrointestinal AEs, including 
diarrhea and abdominal pain, were of special interest and 
found to occur at similar rates in maralixibata-treated 
and placebo-treated participants (overall gastrointesti-
nal, 52% versus 58%; diarrhea, 32% versus 50%; abdom-
inal pain, 16% versus 17%, respectively). There was no 
clinically significant difference in change in weight 
from baseline to week 13 in maralixibat-treated versus 
placebo-treated participants (maralixibata, 0.73 ± 0.12 
kg; placebo, 0.69 ± 0.17 kg; mean ± SEM, P = 0.842).
Criteria for identification of drug-induced liver 
injury (DILI) or therapy-related hepatotoxicity in 
the setting of chronic cholestasis are not well defined 
either in the literature or at a regulatory level. For the 
purposes of this study, specific changes from base-
line were developed a priori as potential safety signals 
requiring enhanced monitoring and stopping rules 
were established (Supporting Table S13). There were 
no participants in either the maralixibat-treated or 
placebo-treated groups who met these stopping crite-
ria (data not shown). The criteria were also not met if 
baseline was defined as the average of screening and 
baseline laboratory values (data not shown).
Fat-soluble vitamin levels were also examined as a 
potential safety signal given the profound cholestasis 
in these participants, the high dosing requirements 
of fat-soluble vitamins as part of their routine care, 
and the potential for changes in intestinal luminal 
bile acid concentrations. Changes were character-
ized relative to baseline and as shifts from sufficient 
to insufficient or from insufficient to sufficient, as 
defined (Supporting Table S14).(11) In general, the 
taBle 2. analysis oF seCondary eFFiCaCy endpoints: CHange From Baseline to WeeK 13
Change From Baseline Treatment Compared to Placebo








(1) 95% CI P value
Difference in 
LS Means 
(SEM) 95% CI P value
Serum bile acid (μmol/L)
70 μg/kg/day 7 392 (126.8) –117 (46.2) (–212, –23) 0.016 –107 (57.2) (–224, 10) 0.071
140 μg/kg/day 11 151 (37.3) –40 (34.9) (–111, 31) 0.256 –30 (47.5) (–127, 67) 0.534
280 μg/kg/day 6 188 (44.0) –27 (46.3) (–122, 67) 0.558 –17 (56.5) (–132, 98) 0.766
Maralixibat* 17 164 (28.2) –34 (29.2) (–93, 26) 0.255 –23 (43.6) (–112, 65) 0.594
Maralixibata 24 231 (45.6) –62 (23.9) (–111, –13) 0.015 –51 (40.6) (–134, 32) 0.216
Placebo 12 205 (46.9) –10 (32.7) (–77, 56) 0.751
Total bilirubin (mg/dL)
70 μg/kg/day 7 7.96 (3.39) –0.29 (0.38) (–1.06, 0.48) 0.447 –0.39 (0.47) (–1.35, 0.56) 0.407
140 μg/kg/day 11 3.36 (1.06) –0.35 (0.30) (–0.97, 0.26) 0.251 –0.46 (0.42) (–1.31, 0.40) 0.284
280 μg/kg/day 6 4.22 (2.10) –0.80 (0.40) (–1.62, 0.02) 0.054 –0.91 (0.49) (–1.92, 0.10) 0.076
Maralixibat* 17 3.66 (0.97) –0.58 (0.25) (–1.09, –0.06) 0.029 –0.68 (0.38) (–1.47, 0.10) 0.086
Maralixibata 24 4.92 (1.23) –0.48 (0.21) (–0.91, –0.06) 0.027 –0.59 (0.35) (–1.31, 0.13) 0.107
Placebo 12 6.41 (1.95) 0.10 (0.28) (–0.48, 0.68) 0.719
Alanine aminotransferase (U/L)
70 μg/kg/day 7 155 (33.7) 15 (17.9) (–22, 51) 0.422 27 (22.8) (–20, 73) 0.253
140 μg/kg/day 11 117 (17.4) 13 (14.9) (–17, 44) 0.383 25 (21.0) (–18, 68) 0.241
280 μg/kg/day 6 191 (42.4) 30 (19.6) (–10, 70) 0.142 41 (23.7) (–7, 90) 0.090
Maralixibat* 17 143 (20.0) 21 (12.1) (–3, 46) 0.086 33 (18.6) (–5, 71) 0.082
Maralixibata 24 146 (16.9) 19 (10.0) (–1, 40) 0.066 31 (17.3) (–4, 66) 0.082
Placebo 12 188 (26.9) –12 (14.0) (–40, 17) 0.400
Note: Abbreviation: LS, least squares.
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number of participants who changed their sufficiency 
status during the course of the study was low. In the 
maralixibat group, vitamin D levels changed in equal 
percentages to insufficient and sufficient during the 
study (13% for each). Vitamin A levels became insuf-
ficient in 1 participant treated with maralixibat, while 
vitamin E levels became sufficient in 2 participants 
treated with maralixibat. Excess levels of vitamin A 
(n = 4) and vitamin D (n = 1) were observed at week 
13 of maralixibat therapy. In 3 participants treated 
with maralixibat, the international normalized ratio 
increased as a potential marker of change in vitamin 
K sufficiency. None of these changes were observed in 
the placebo group.
Fig. 5. Box and whisker plots of changes in measured laboratory parameters over time. (A) Total bilirubin; (B) alanine aminotransferase; 
(C) serum bile acids; (D) C4. Maralixibata was compared to placebo. Data are represented as follows: mean, o or + inside the box; 
median, line inside the box; box, interquartile range (25-75 percentiles); whiskers, values within 1.50 times interquartile range; outliers, 
individual data points beyond the whiskers.
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Discussion
Data from this randomized placebo-controlled 
trial in children with ALGS suggest that maralixi-
bat is generally safe, well-tolerated, and may reduce 
pruritus. The first predefined analysis of the primary 
endpoint did not meet the predefined statistical 
level for efficacy, while other analyses of the pri-
mary endpoint did. The reason for the heteroge-
neous responses cannot be determined from these 
investigations, and further study to assess safety and 
efficacy of maralixibat as a treatment for cholesta-
sis-associated pruritus in children with cholestasis 
is warranted.
Fig. 5. (Continued)
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The expected therapeutic benefit of maralixibat is 
based on the response of patients with ALGS to sur-
gical interruption of the enterohepatic circulation, 
 primarily through PEBD or IE.(2,3,7) This response 
may not be as dramatic as has been observed in some 
individuals with progressive familial intrahepatic 
cholestasis. In general, responses tend to be favorable, 
with improvement in pruritus, xanthomas, and hyper-
cholesterolemia. There are less clear or minimal effects 
on SBAs, bilirubin, and ALT.(3) In most cases, surgery is 
performed for severe pruritus equivalent to CSS grade 
4. Not all patients have complete resolution of their 
pruritus, but most have clinically significant improve-
ment, equivalent to a reduction in CSS of 2 or more. 
ItchRO was not available to assess response in any of 
these published experiences. The favorable response to 
surgery has been generally documented over the first 
12 to 24 months after surgery. None of the published 
studies of surgical intervention have examined results 
at 3 months after surgery, so direct comparison to this 
study is not possible. The relatively short time course 
of the current study may not have fully captured the 
potential efficacy of maralixibat. Ongoing long-term 
follow-up studies (NCT02047318, NCT02117713) 
may shed light on this matter, although these stud-
ies are not placebo controlled, with the exception of a 
4-week, randomized, placebo-controlled withdrawal of 
maralixibat (NCT02160782).
Fig. 6. Spaghetti plots of changes in the clinician scratch scale over time. Each line represents an individual participant. The 
participants are grouped by the target dose of the study drug.
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The primary endpoint for this study was pruritus as 
assessed by ItchRO(Obs). This endpoint was chosen 
in recognition of the profound impact of pruritus on 
children with ALGS and on their families. Pruritus is 
notoriously difficult to objectively assess in clinical set-
tings, and this challenge is amplified in research trials. 
Instruments for assessing pruritus can broadly be cate-
gorized into patient-reported outcome tools and those 
that are independent of patient reporting, such as the 
CSS. An intermediate level of reporting is by parental/
guardian observation of children, as was reported in 
this study. No single instrument, including actigraphy, 
has been fully validated to capture the multidimen-
sional features of pruritus and its change over time, 
especially in children. To address this for this clinical 
trial, a novel tool, ItchRO, was developed using a rig-
orous tool development methodology to assess pruri-
tus in children with cholestasis, specifically those with 
ALGS.(8) Detailed analyses of ItchRO and the effect 
of maralixibat on quality of life, which is complex and 
beyond the scope of this report, will be the subject of a 
future report from this study.(12)
The placebo effect in this study was evident and 
highlights the critical need for a double-blind place-
bo-controlled study design in clinical trials addressing 
pruritus. It is well recognized that somatic symptoms, 
such as pain and fatigue, can be improved by placebo 
due to positive expectations, but the effect of placebo 
on itch in cholestasis has not been extensively stud-
ied. In the placebo-treated arm of a study assessing the 
effect of another ASBTi (GSK2330672) on pruritus 
in patients with primary biliary cholangitis (PBC), 
there was a 23% improvement in itch on a 10-point 
numerical rating scale.(13) A similar reduction of 0.6 
in ItchRO was observed in the unpublished results of 
IMAGO (NCT01903460).
Pharmacologic inhibition of ASBT is an evolving 
potential approach to the treatment of constipation, 
cholestasis, diabetes, and fatty liver disease.(14) The 
findings of the current study should be considered in 
the context of recent related investigations of choles-
tatic liver disease. The only peer-reviewed published 
report of an ASBTi is in adults with PBC.(13) This 
was a 2-week, double-blind, randomized, placebo-con-
trolled, crossover phase 2a trial of 22 patients receiving 
GSK2330672 (NCT01899703). The primary end-
points of the study were safety and tolerability, which 
were deemed acceptable. Pruritus, quantified using 
three separate scores, was reduced by 30% to 57% with 
2 weeks of therapy. Decreased SBAs and compensa-
tory increases in C4 supported the expected biological 
effect on intestinal bile acid transport. The biochem-
ical characteristics of cholestasis at baseline in the 
adult participants of the PBC study were less severe 
than in the children with ALGS in the current study 
(e.g., mean TB was 12.2 µM for PBC and 90.6 µM for 
ALGS; SBAs were 48.6 µM for PBC and 216.3 µM for 
ALGS). Additional studies of an ASBTi in cholesta-
sis have been preliminarily reported as abstracts or as 
registered trials. An open-label dose-ranging phase 
II study of A4250 (Albireo Pharma) in 19 children 
with a variety of cholestatic conditions demonstrated 
improvement in pruritus in 14 children, as assessed 
by a visual itch score recorded by caretakers.(15) The 
small sample size (14 participants with maralixibat and 
6 participants with placebo) in IMAGO, which was 
conducted in the United Kingdom, may have limited 
the power of the study to identify a potential effect 
(NCT01903460).
SBA levels are an attractive choice as an endpoint 
for the use of an ASBTi in pediatric cholestasis. Levels 
represent a complex dynamic interplay of intesti-
nal absorption and hepatic extraction, synthesis, and 
excretion. The experiences in this study of ALGS 
raise important concerns about this possible endpoint. 
First, there is significant variability in SBAs in children 
with ALGS, and this necessitates a fairly large sam-
ple size to demonstrate a potential therapeutic effect. 
Ursodeoxycholic acid, which was used by 84% of the 
participants, is not actively transported by ASBT; as 
such, its common use in ALGS may contribute signifi-
cantly to SBAs and thus complicate the use of SBAs 
to define the ASBTi effect. Fecal bile acid determina-
tion, which would be a direct assay of ASBTi activity, 
is cumbersome and was not employed in this study. 
Changes in C4 are used as an alternative surrogate 
marker of ASBTi activity because diminished ileal 
absorption is predicted to lead to reduced fibroblast 
growth factor 19-mediated ileal signaling to the liver 
and derepression of bile acid biosynthesis reflected by 
elevated C4. In this study, C4 levels were highly vari-
able and may in part explain the lack of a statistically 
significant increase with maralixibat. The magnitude 
of changes in C4 suggests that a maximal ASBTi effect 
was not induced by the doses of drug used in this study. 
Alternatively, luminal bile acids in children with severe 
cholestasis with ALGS may be so low that an effect 
on C4 is difficult to demonstrate. LDL-C levels were 
reduced, consistent with enhanced conversion of cho-
lesterol to bile acids, as has been observed in surgical 
interruption of the enterohepatic circulation.(16) Total 
cholesterol levels, which are reflective of lipoprotein X 
Hepatology CommuniCations, Vol. 2, no. 10, 2018 sHneider et al.
1197
accumulation, would not be expected to be impacted as 
quickly by an ASBTi.
No significant safety issues were identified in this 
study of maralixibat. One of the potentially attractive 
features of an ASBTi is that it can act at the luminal ileal 
brush border membrane without significant systemic 
absorption, thereby reducing potential risk of toxicity. 
The major potential predicted side effect of an ASBTi 
relates to sequelae of bile acid malabsorption with 
related diarrhea and abdominal pain. Approximately 
half of the children who received maralixibat had gas-
trointestinal symptoms, none of which were severe. 
The critical importance of a blinded placebo control 
was reconfirmed by the finding of similar gastrointes-
tinal problems in the placebo-treated group. One of the 
complexities of clinical trials in cholestatic liver disease 
is the lack of understanding of approaches to monitor-
ing for adverse effects on the liver itself.(17) DILI is a 
major concern in the development of new drugs but is 
poorly characterized in chronic liver disease, especially 
cholestatic disease. Cholestatic features can be the most 
worrisome for serious drug-related injury. Given the 
exceptionally limited systemic absorption of maralixibat, 
DILI was of limited concern. Despite this, prospective 
methods for monitoring potential drug toxicity needed 
to be established. The parameters chosen in this study 
(Supporting Table S13) did not reveal hepatotoxicity 
related to this treatment approach. These parameters 
might be considered for future studies in ALGS. The 
placebo treatment group along with the screening and 
enrollment laboratory studies provide additional novel 
insight into the natural variability of key liver parame-
ters in ALGS that may guide future clinical studies of 
novel pharmacologic agents in pediatric cholestasis.
A major limitation of this study is the unexpected 
lack of response in the children receiving 280 µg/kg/
day of maralixibat. It is unlikely that this is the result 
of an excessive dose of drug, especially in light of the 
relatively limited increase in C4. ALGS is a rare dis-
order, and the number of participants in the study was 
selected more on practical rather than power consider-
ations. The randomization process in this small phase 
2b study allocated only 6 participants to 280 µg/kg/day 
dosing, and this limited sample size may have skewed 
the findings. Both the placebo and 280-µg/kg/day 
groups were characterized by a preponderance of chil-
dren younger than 5 years of age (Supporting Table S6). 
ItchRO is a new tool that has had limited performance 
experience, and it is unclear if it performs equally at all 
ages. The positive CSS response in the 280-µg/kg/day 
group suggests that this could be an issue.
Despite the inconsistent findings of the analyses of 
the primary endpoint of this study, the data in total 
suggest that maralixibat is generally safe and well tol-
erated and may reduce pruritus in ALGS. There is a 
clear unmet and significant need in the management of 
pruritus in ALGS and other cholestatic liver diseases 
in children. Continued investigation of maralixibat is 
warranted. These studies should continue to consider 
ongoing potential placebo effects and seek methods to 
determine dose responses on ileal ASBT activity and 
their relationship to biochemical and symptomatic 
effects.
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